Ocugen has initiated its global Phase III ArMaDa3 trial of OCU410, an investigational gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD), with the dosing of the first patient.
The randomised, controlled, multi-centre study is being conducted across sites in Canada, Latin America, Europe, and the US, and will enrol 237 participants.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
OCU410 is designed to be administered as a single subretinal injection.
The therapy delivers the human retinoid-related orphan receptor alpha gene using an AAV5 vector with the aim of targeting multiple relevant disease pathways, including complement overactivation, chronic inflammation, oxidative stress, and lipid dysregulation.
This approach differs from available treatments in the US, which are complement inhibitors administered through repeated eye injections and address individual disease pathways.
The US Food and Drug Administration granted OCU410 regenerative medicine advanced therapy (RMAT) designation in July 2026, following Phase II data.
The global Phase III study is randomising participants with GA due to dAMD in a 2:1 ratio to receive either OCU410 or no treatment.
The main goal is to measure the rate of change in the square root-transformed GA lesion area per year using fundus autofluorescence at several time points over 12 months.
Secondary outcomes include the proportion of subjects experiencing significant loss in low-luminance visual acuity and the rate of change in ellipsoid zone area loss as measured by SD-OCT.
Ocugen chairman, CEO and co-founder Dr Shankar Musunuri said: “Dosing the first patient in our global Phase III trial, just weeks after receiving RMAT designation, marks a defining moment for the OCU410 programme—and for the millions of people living with geographic atrophy.”
The Phase III trial design aligns with guidance from the FDA, as confirmed in a Type B End-of-Phase II meeting in July 2026.
Ocugen anticipates submission of a biologics license application in 2028, and discussions are underway with the European Medicines Agency (EMA) for possible registration in Europe based on this trial.
Support for advancement into Phase III is drawn from 12-month Phase II results showing a 31% reduction in lesion growth and no OCU410-related serious adverse events.
Earlier this year, Ocugen reported positive results for OCU410 in GA secondary to dAMD.
Cell & Gene therapy coverage on Clinical Trials Arena is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
